TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04263402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
Study: NCT01715064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of moderate-intensity exercise
Study: NCT01431859

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergovit Birch pollen
Description: Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
Study: NCT03265613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
Study: NCT03128359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo PBSC HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo PBSC HCT
Study: NCT01168206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TK3
Description: Tritofano 160mg / Timina140mg and starch 150 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 capsule, 3 times per day
Description: Placebo
Study: NCT02530476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.
Study: NCT00130039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel 75mg once a day plus placebo of cilostazol twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
Study: NCT00642707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140 (humanized monoclonal antibody to CCR5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140 (humanized monoclonal antibody to CCR5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140 (humanized monoclonal antibody to CCR5)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT05353413

Intervention type: DEVICE
Group type: OTHER
Intervention: Neuroimaging
Description: Magnetic resonance diffusion tensor imaging of the brain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: Magnetic resonance diffusion tensor imaging of the brain

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VEP - visual evoked potential
Description: Electrophysiology of the visual pathway.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VEP - visual evoked potential
Description: Electrophysiology of the visual pathway.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ophthalmology examination.
Description: Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ophthalmology examination.
Description: Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
Study: NCT03165786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FREE
Description: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Study: NCT01562886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 26mg
Study: NCT04803474

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Description: Measurement of blood values, questionnaire scores and measurements of hormone levels in hair

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Description: Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
Study: NCT01165125

Intervention type: DRUG
Group type: OTHER
Intervention: FF / GW642444
Description: 200mcg/25mcg Novel DPI

Intervention type: DRUG
Group type: OTHER
Intervention: FF / GW642444
Description: 200mcg/25mcg Novel DPI

Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole
Description: 400mcg overencapsulated tablets

Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole (placebo to match)
Description: placebo to match overencapsulated tablets
Study: NCT01983592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic medicine
Description: Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unmedicated lactose/sucrose globule
Study: NCT03420144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
Study: NCT03693144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full LIITA3H App
Description: This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial LIITA3H App
Description: This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.

Intervention type: OTHER
Group type: OTHER
Intervention: LIITA3H Location only
Description: This is a version of the LIITA3H mobile app that will only track participants' location.
Study: NCT02861339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opthalmologic measure with DM OPD scan III (Nidek)
Description: Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
Study: NCT02607410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Study: NCT04160312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure™ (Proprietary Urolithin A)
Description: Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: 100% Pomegranate juice (approximately 1 glass equivalent)
Study: NCT00954161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helping behaviour curriculum
Description: The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First aid only curriculum
Description: Two hours training on first aid for alcohol and drug incidents
Study: NCT01545596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Notification Group
Description: Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
Study: NCT03306433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UDMA-K18 smooth surface sealant
Description: The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: UDMA-K18 smooth surface sealant
Description: The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
Study: NCT04335448

Intervention type: OTHER
Intervention: No intervention is planed
Description: No intervention is planed
Study: NCT04171505

Intervention type: DRUG
Intervention: HPV vaccine
Description: . Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account.
Study: NCT03135431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Salpingectomy
Description: Surgical removal of entire fallopian tubes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Tubal Ligation
Description: Surgical tying, cutting, or removal of a portion of the fallopian tubes
Study: NCT05214066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
Study: NCT02990975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study: NCT00711152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol-driven care under JADE Program
Description: The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol-driven care under JADE Program
Description: The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional support by CHW
Description: Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
Study: NCT02848456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Max Voluntary Isometric Contraction
Description: A 10 second plantar flexion maximal voluntary isometric contraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SM+MVIC
Description: The spinal manipulation immediately preceding the maximal voluntary isometric contraction
Study: NCT02544347

Intervention type: OTHER
Group type: OTHER
Intervention: gingival crevicular fluid
Description: gingival crevicular fluid was collected

Intervention type: OTHER
Group type: OTHER
Intervention: gingival crevicular fluid
Description: gingival crevicular fluid was collected

Intervention type: OTHER
Group type: OTHER
Intervention: gingival crevicular fluid
Description: gingival crevicular fluid was collected

Intervention type: OTHER
Group type: OTHER
Intervention: gingival crevicular fluid
Description: gingival crevicular fluid was collected

Intervention type: OTHER
Group type: OTHER
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed

Intervention type: OTHER
Group type: OTHER
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed
Study: NCT01970644

Intervention type: RADIATION
Intervention: Gamma knife radiosurgery
Description: Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
Study: NCT02276742

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Theory
Description: focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Theory
Description: focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
Study: NCT00529243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
Study: NCT02970591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional dietary advice and low FODMAP content
Description: Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Medical treatment
Description: Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
Study: NCT04202666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: convex skin barrier
Description: Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
Study: NCT04896190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position
Description: Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
Study: NCT04771026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
Study: NCT03429322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Care and Resource Facilitation
Description: The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive and provide usual and customary care in their communities.
Study: NCT01216397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin (standard batch)
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin (side batch)
Description: Fixed dose combination tablet
Study: NCT02915887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Taping
Description: Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
Study: NCT04387929

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of anti-COVID-19 antibody level
Description: Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of anti-COVID-19 antibody level
Description: Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
Study: NCT02949024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVT Aflibercept
Description: IVT aflibercept \[2 mg (50 µL)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC CLS-TA
Description: \[4 mg (100 µL)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC CLS-TA
Description: \[4 mg (100 µL)\]
Study: NCT03108521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100mg.QD for 3 months